EMCDDA news

The new EU Drugs Strategy 2021–25 makes explicit that the European response to drugs should be evidence-based and delivered through a balanced and integrated approach, which ultimately must be judged on its impact on the health, safety and wellbeing of our citizens. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is tasked with helping to provide the evidence needed to ensure that European policies and actions on drugs are effective, well-targeted and responsive to new threats and challenges. 09.06.2021  EMCDDA DIRECTOR ALEXIS GOOSDEEL

How has the COVID-19 pandemic affected drug use and supply? What drugs are causing the most concern today? What are the latest trends in drug production and trafficking? Find out more when the EU drugs agency (EMCDDA) launches its European Drug Report 2021: Trends and Developments in a live online media event on 9 June. Based on data from 29 countries (EU 27, Turkey and Norway), the report delivers the latest overview of the drug situation in Europe. 20.05.2021  LATEST ANNUAL TRENDS REPORT FROM THE EMCDDA

The 2020 findings from the largest European project in the science of wastewater analysis are revealed today in Wastewater analysis and drugs — a European multi-city study, published by the Europe-wide SCORE group, in association with the EU drugs agency (EMCDDA) (1)(2). The project analysed wastewater in 82 European cities (18 countries) to explore the drug-taking behaviours of their inhabitants. 17.05.2021  New study on wastewater analysis puts city drug use in the spotlight

In the last few weeks, three US states have legalised cannabis for recreational purposes, all via the legislature and not via public ballots. New York, Virginia and New Mexico will begin by permitting cannabis use in private and home cultivation, for adults aged over 21 (out of sight and away from children). The intention is to introduce commercial markets in the coming years, after detailed regulatory requirements are agreed. 03.05.2021